Request Deal Involvement

Goldman Sachs Alternatives led a $105m Series B round in Attovia Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

or

Principals

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

MARSHALL WACE

bidder

MARSHALL WACE

GOLDMAN SACHS ALTERNATIVES

bidder

GOLDMAN SACHS ALTERNATIVES

ATTOVIA THERAPEUTICS

target

ATTOVIA THERAPEUTICS

ILLUMINA VENTURES

bidder

ILLUMINA VENTURES

NEXTECH

bidder

NEXTECH

REDMILE GROUP

bidder

REDMILE GROUP

ECOR1 CAPITAL

bidder

ECOR1 CAPITAL

LOGOS CAPITAL

bidder

LOGOS CAPITAL

VENBIO LLC

bidder

VENBIO LLC

FRAZIER LIFE SCIENCES

bidder

FRAZIER LIFE SCIENCES

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Goldman Sachs Alternatives led a $105m Series B round in Attovia Therapeutics.